CLINICAL TRIALS PROFILE FOR PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
✉ Email this page to a colleague
All Clinical Trials for PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00518466 ↗ | Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults | Completed | VIVUS, Inc. | Phase 1 | 2007-07-01 | The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine. |
| NCT00563368 ↗ | A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Completed | Medpace, Inc. | Phase 3 | 2007-12-01 | The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose. |
| NCT00563368 ↗ | A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Completed | VIVUS, Inc. | Phase 3 | 2007-12-01 | The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose. |
| NCT00600067 ↗ | A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Completed | Sentrx | Phase 2 | 2008-01-01 | The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial. |
| NCT00600067 ↗ | A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Completed | Synteract, Inc. | Phase 2 | 2008-01-01 | The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial. |
| NCT00600067 ↗ | A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Completed | VIVUS, Inc. | Phase 2 | 2008-01-01 | The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial. |
| NCT00737633 ↗ | Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults | Terminated | Sentrx | Phase 2 | 2008-08-01 | This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to enroll into this study will receive study drug. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Condition Name
Clinical Trial Locations for PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Trials by Country
Clinical Trial Progress for PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Clinical Trial Phase
Clinical Trial Sponsors for PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Sponsor Name
